← All trials
NCT04595942
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 19, 2020
- Primary completion
- Oct 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Oct 22, 2020
- Last posted
- Nov 23, 2020
- Enrollment
- 1375
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TehranLead sponsor
- Isfahan UniversityCollaborator
- Mahidol UniversityCollaborator
- University of TehranReponsible party - principal investigator
- Shahid Beheshti University of Medical SciencesCollaborator
- Rajaie Cardiovascular Medical and Research CenterCollaborator
- AJA University of Medical SciencesCollaborator
- Tehran University of Medical ScienceCollaborator
- Tehran University of Medical ScienceStudy director
- Tehran University of Medical ScienceStudy chair
- Imam Khomeini HospitalCollaborator
- Ahvaz Jundishapur University of Medical SciencesCollaborator
- Urmia University of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.